Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Estimates Preliminary Q2 Revenues of $1.7M to $1.8M

NEW YORK (GenomeWeb News) — Cancer Genetics today said in a regulatory document that its second-quarter revenues are expected to be in the range of $1.7 million and $1.8 million.

That compares to $1.1 million in the second quarter of 2012.

Figures for the three monthes ended June 30, 2013 include no grant revenues, compared to $184,500 a year ago. Revenue increase for the recently completed period "substantially" resulted from increased revenues from a clinical trials client, the Rutheford, N.J.-firm, which went public in April, said in a document filed with the US Securities and Exchange Commission.

Preliminary gross profit for the second quarter is estimated at between $520,000 and $580,000, it added, while preliminary operating loss is anticipated at between $1.6 million and $1.9 million. .

Cancer Genetics had about $1.9 million in cash and cash equivalents at the end of the quarter. Last month, it filed a preliminary prospectus to offer $15 million in a public offering of its stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.